Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 157.19 Billion JPY | 58.12% |
| 2022 | 99.41 Billion JPY | 2.51% |
| 2021 | 96.98 Billion JPY | 26.84% |
| 2020 | 76.46 Billion JPY | 34.91% |
| 2019 | 56.68 Billion JPY | -3.91% |
| 2018 | 58.98 Billion JPY | -15.11% |
| 2017 | 69.48 Billion JPY | 44.5% |
| 2016 | 48.08 Billion JPY | 1.55% |
| 2015 | 47.35 Billion JPY | 8.11% |
| 2014 | 43.8 Billion JPY | 200.37% |
| 2013 | 14.58 Billion JPY | 114.61% |
| 2012 | 6.79 Billion JPY | -8.06% |
| 2011 | 7.39 Billion JPY | -17.81% |
| 2010 | 8.99 Billion JPY | -15.75% |
| 2009 | 10.67 Billion JPY | -13.7% |
| 2008 | 12.36 Billion JPY | -28.94% |
| 2007 | 17.4 Billion JPY | -24.96% |
| 2006 | 23.19 Billion JPY | -8.35% |
| 2005 | 25.3 Billion JPY | 156.15% |
| 2004 | 9.87 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 152.33 Billion JPY | -2.65% |
| 2024 Q2 | 156.48 Billion JPY | 2.75% |
| 2024 Q1 | 152.29 Billion JPY | -3.12% |
| 2023 Q3 | 149.43 Billion JPY | 43.6% |
| 2023 Q4 | 157.19 Billion JPY | 5.19% |
| 2023 FY | 157.19 Billion JPY | 58.12% |
| 2023 Q2 | 104.06 Billion JPY | 5.41% |
| 2023 Q1 | 98.71 Billion JPY | -0.7% |
| 2022 FY | 99.41 Billion JPY | 2.51% |
| 2022 Q4 | 99.41 Billion JPY | 4.46% |
| 2022 Q1 | 95.85 Billion JPY | -1.17% |
| 2022 Q2 | 91.23 Billion JPY | -4.82% |
| 2022 Q3 | 95.16 Billion JPY | 4.31% |
| 2021 FY | 96.98 Billion JPY | 26.84% |
| 2021 Q1 | 79.37 Billion JPY | 3.8% |
| 2021 Q2 | 81.34 Billion JPY | 2.49% |
| 2021 Q3 | 88.95 Billion JPY | 9.35% |
| 2021 Q4 | 96.98 Billion JPY | 9.03% |
| 2020 Q2 | 51.07 Billion JPY | -3.38% |
| 2020 Q1 | 52.86 Billion JPY | -6.73% |
| 2020 Q4 | 76.46 Billion JPY | 4.29% |
| 2020 FY | 76.46 Billion JPY | 34.91% |
| 2020 Q3 | 73.32 Billion JPY | 43.55% |
| 2019 Q3 | 59.32 Billion JPY | 1.52% |
| 2019 FY | 56.68 Billion JPY | -3.91% |
| 2019 Q2 | 58.43 Billion JPY | -5.51% |
| 2019 Q1 | 61.84 Billion JPY | 0.0% |
| 2019 Q4 | 56.68 Billion JPY | -4.45% |
| 2018 Q1 | 69.48 Billion JPY | -6.04% |
| 2018 Q3 | 63.4 Billion JPY | -3.22% |
| 2018 Q2 | 65.51 Billion JPY | -5.72% |
| 2018 FY | 58.98 Billion JPY | -15.11% |
| 2017 Q1 | 48.08 Billion JPY | -8.4% |
| 2017 FY | 69.48 Billion JPY | 44.5% |
| 2017 Q4 | 73.94 Billion JPY | 34.71% |
| 2017 Q3 | 54.89 Billion JPY | 1.93% |
| 2017 Q2 | 53.85 Billion JPY | 11.99% |
| 2016 FY | 48.08 Billion JPY | 1.55% |
| 2016 Q4 | 52.49 Billion JPY | 9.36% |
| 2016 Q1 | 47.35 Billion JPY | -2.04% |
| 2016 Q3 | 48 Billion JPY | -12.6% |
| 2016 Q2 | 54.92 Billion JPY | 15.98% |
| 2015 Q2 | 45.19 Billion JPY | 3.19% |
| 2015 FY | 47.35 Billion JPY | 8.11% |
| 2015 Q3 | 42.41 Billion JPY | -6.16% |
| 2015 Q4 | 48.34 Billion JPY | 13.98% |
| 2015 Q1 | 43.8 Billion JPY | 175.95% |
| 2014 Q4 | 15.87 Billion JPY | 5.47% |
| 2014 Q3 | 15.04 Billion JPY | 2.19% |
| 2014 Q2 | 14.72 Billion JPY | 1.0% |
| 2014 Q1 | 14.58 Billion JPY | 122.49% |
| 2014 FY | 43.8 Billion JPY | 200.37% |
| 2013 FY | 14.58 Billion JPY | 114.61% |
| 2013 Q1 | 6.79 Billion JPY | -6.12% |
| 2013 Q2 | 6.27 Billion JPY | -7.59% |
| 2013 Q4 | 6.55 Billion JPY | -5.31% |
| 2013 Q3 | 6.92 Billion JPY | 10.23% |
| 2012 Q3 | 7.08 Billion JPY | 3.63% |
| 2012 Q1 | 7.39 Billion JPY | -3.82% |
| 2012 FY | 6.79 Billion JPY | -8.06% |
| 2012 Q4 | 7.23 Billion JPY | 2.19% |
| 2012 Q2 | 6.83 Billion JPY | -7.53% |
| 2011 FY | 7.39 Billion JPY | -17.81% |
| 2011 Q4 | 7.68 Billion JPY | -7.78% |
| 2011 Q1 | 8.99 Billion JPY | -5.48% |
| 2011 Q3 | 8.33 Billion JPY | -2.27% |
| 2011 Q2 | 8.52 Billion JPY | -5.18% |
| 2010 FY | 8.99 Billion JPY | -15.75% |
| 2010 Q2 | 10.7 Billion JPY | 0.32% |
| 2010 Q3 | 10.14 Billion JPY | -5.29% |
| 2010 Q1 | 10.67 Billion JPY | -4.79% |
| 2010 Q4 | 9.51 Billion JPY | -6.19% |
| 2009 Q3 | 11.76 Billion JPY | 0.0% |
| 2009 Q4 | 11.21 Billion JPY | -4.72% |
| 2009 FY | 10.67 Billion JPY | -13.7% |
| 2009 Q1 | 12.36 Billion JPY | -7.39% |
| 2008 Q4 | 13.35 Billion JPY | 0.0% |
| 2008 FY | 12.36 Billion JPY | -28.94% |
| 2007 FY | 17.4 Billion JPY | -24.96% |
| 2006 FY | 23.19 Billion JPY | -8.35% |
| 2005 FY | 25.3 Billion JPY | 156.15% |
| 2004 FY | 9.87 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -2285.648% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -12876.278% |
| GNI Group Ltd. | 62.39 Billion JPY | -151.943% |
| Linical Co., Ltd. | 18.53 Billion JPY | -747.89% |
| Trans Genic Inc. | 9.81 Billion JPY | -1502.263% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -2690.095% |
| Soiken Holdings Inc. | 6.94 Billion JPY | -2163.101% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -2602.699% |
| AnGes, Inc. | 28.89 Billion JPY | -444.078% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -18025.508% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -9612.081% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -2999.77% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -3513.838% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -6361.462% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -6523.406% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | -2168.279% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -8875.286% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -2991.072% |
| PeptiDream Inc. | 67.12 Billion JPY | -134.181% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -7603.526% |
| Ribomic Inc. | 3.54 Billion JPY | -4331.537% |
| SanBio Company Limited | 5.04 Billion JPY | -3014.502% |
| Healios K.K. | 15.15 Billion JPY | -937.268% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -12677.655% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -5112.135% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -10563.601% |
| StemRIM | 9.08 Billion JPY | -1631.256% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -2184.942% |
| FunPep Company Limited | 2.49 Billion JPY | -6210.299% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -5903.001% |
| Stella Pharma Corporation | 3.82 Billion JPY | -4014.461% |
| TMS Co., Ltd. | 3.55 Billion JPY | -4322.191% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -2620.185% |
| Cuorips Inc. | 6.18 Billion JPY | -2441.708% |
| K Pharma,Inc. | 3.31 Billion JPY | -4643.592% |
| Takara Bio Inc. | 123.2 Billion JPY | -27.589% |
| ReproCELL Incorporated | 9.05 Billion JPY | -1636.49% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -5689.299% |
| StemCell Institute Inc. | 6.54 Billion JPY | -2302.51% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | -2149.293% |
| CellSeed Inc. | 2.46 Billion JPY | -6275.215% |